Nisa Investment Advisors LLC Sells 70,629 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Nisa Investment Advisors LLC lessened its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 34.6% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 133,209 shares of the company's stock after selling 70,629 shares during the quarter. Nisa Investment Advisors LLC's holdings in Elanco Animal Health were worth $1,399,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. CoreCap Advisors LLC purchased a new stake in shares of Elanco Animal Health in the 4th quarter valued at approximately $29,000. NBC Securities Inc. acquired a new position in Elanco Animal Health in the 1st quarter valued at approximately $40,000. Parallel Advisors LLC increased its stake in Elanco Animal Health by 92.2% in the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock valued at $41,000 after buying an additional 1,852 shares during the period. Versant Capital Management Inc increased its stake in Elanco Animal Health by 65.9% in the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock valued at $46,000 after buying an additional 1,740 shares during the period. Finally, Jones Financial Companies Lllp increased its stake in Elanco Animal Health by 95.6% in the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock valued at $51,000 after buying an additional 2,059 shares during the period. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Price Performance

Shares of Elanco Animal Health stock traded down $0.10 during trading on Friday, hitting $14.87. 806,414 shares of the company's stock traded hands, compared to its average volume of 5,027,157. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.71 and a quick ratio of 1.46. The firm's fifty day moving average price is $13.76 and its 200 day moving average price is $11.77. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $15.78. The company has a market cap of $7.38 billion, a PE ratio of 20.07, a PEG ratio of 2.83 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.06. Elanco Animal Health had a net margin of 8.43% and a return on equity of 7.54%. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period last year, the firm posted $0.34 EPS. The firm's quarterly revenue was down 1.0% on a year-over-year basis. Analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on ELAN. Wall Street Zen upgraded shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Leerink Partnrs upgraded shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a report on Thursday. Leerink Partners upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 target price on the stock in a report on Thursday. Finally, Stifel Nicolaus lifted their target price on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a report on Wednesday, July 2nd. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Elanco Animal Health has a consensus rating of "Moderate Buy" and an average target price of $16.00.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.